Immunome (NASDAQ:IMNM) Stock Price Up 9.4% – What’s Next?

Shares of Immunome, Inc. (NASDAQ:IMNM) rose 9.4% on Tuesday . The company traded as high as $21.01 and last traded at $21.11. Approximately 282,944 shares traded hands during trading, a decline of 81% from the average daily volume of 1,521,604 shares. The stock had previously closed at $19.30.

Wall Street Analyst Weigh In

Several brokerages recently commented on IMNM. Guggenheim increased their price objective on shares of Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Lake Street Capital upped their price target on Immunome from $22.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Wedbush reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Immunome in a report on Thursday, January 15th. Finally, Truist Financial initiated coverage on Immunome in a research report on Monday, December 1st. They set a “buy” rating and a $36.00 price objective on the stock. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.45.

Immunome Trading Up 14.8%

The firm has a market cap of $2.51 billion, a P/E ratio of -9.13 and a beta of 2.12. The firm’s 50 day moving average is $22.59 and its two-hundred day moving average is $19.00.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%. Analysts predict that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Insider Activity

In related news, Director Philip Wagenheim sold 36,800 shares of the stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $20.47, for a total transaction of $753,296.00. Following the completion of the sale, the director directly owned 369,347 shares of the company’s stock, valued at approximately $7,560,533.09. This represents a 9.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 7.69% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IMNM. Assetmark Inc. acquired a new position in shares of Immunome during the 3rd quarter worth approximately $39,000. BNP Paribas Financial Markets boosted its holdings in shares of Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after buying an additional 2,909 shares during the last quarter. Strs Ohio bought a new position in shares of Immunome in the fourth quarter valued at $64,000. Tower Research Capital LLC TRC increased its holdings in Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after buying an additional 3,802 shares during the last quarter. Finally, BIT Capital GmbH acquired a new position in Immunome during the third quarter worth $69,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.